These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37947293)

  • 1. Discovery of the covalent SARS-CoV-2 M
    Zhang YN; Zhu GH; Liu W; Chen XX; Xie YY; Xu JR; Jiang MF; Zhuang XY; Zhang WD; Chen HZ; Ge GB
    J Med Virol; 2023 Nov; 95(11):e29208. PubMed ID: 37947293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and characterization of the covalent SARS-CoV-2 3CL
    Zhang YN; Zhu GH; Liu W; Xiong Y; Hu Q; Zhuang XY; Jia GH; Zhang WD; Ge GB
    Phytomedicine; 2023 Jun; 114():154796. PubMed ID: 37037086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flavonoids in Ampelopsis grossedentata as covalent inhibitors of SARS-CoV-2 3CL
    Xiong Y; Zhu GH; Zhang YN; Hu Q; Wang HN; Yu HN; Qin XY; Guan XQ; Xiang YW; Tang H; Ge GB
    Int J Biol Macromol; 2021 Sep; 187():976-987. PubMed ID: 34333006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening of M
    Altomare A; Baron G; Cambiaghi G; Ferrario G; Zoanni B; Della Vedova L; Fumagalli GM; D'Alessandro S; Parapini S; Vittorio S; Vistoli G; Riso P; Carini M; Delbue S; Aldini G
    Molecules; 2024 Jun; 29(11):. PubMed ID: 38893578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based discovery of thiosemicarbazones as SARS-CoV-2 main protease inhibitors.
    Maltarollo VG; da Silva EB; Kronenberger T; Sena Andrade MM; de Lima Marques GV; Cândido Oliveira NJ; Santos LH; Oliveira Rezende Júnior C; Cassiano Martinho AC; Skinner D; Fajtová P; M Fernandes TH; Silveira Dos Santos ED; Rodrigues Gazolla PA; Martins de Souza AP; da Silva ML; Dos Santos FS; Lavorato SN; Oliveira Bretas AC; Carvalho DT; Franco LL; Luedtke S; Giardini MA; Poso A; Dias LC; Podust LM; Alves RJ; McKerrow J; Andrade SF; Teixeira RR; Siqueira-Neto JL; O'Donoghue A; de Oliveira RB; Ferreira RS
    Future Med Chem; 2023 Jun; 15(11):959-985. PubMed ID: 37435731
    [No Abstract]   [Full Text] [Related]  

  • 6. Identification of SARS-CoV-2 Main Protease Inhibitors from a Library of Minor Cannabinoids by Biochemical Inhibition Assay and Surface Plasmon Resonance Characterized Binding Affinity.
    Liu C; Puopolo T; Li H; Cai A; Seeram NP; Ma H
    Molecules; 2022 Sep; 27(18):. PubMed ID: 36144858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An integrated metabolomic and proteomic approach for the identification of covalent inhibitors of the main protease (M
    Baron G; Borella S; Della Vedova L; Vittorio S; Vistoli G; Carini M; Aldini G; Altomare A
    Talanta; 2023 Jan; 252():123824. PubMed ID: 36027618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of natural catechol derivatives as covalent SARS-CoV-2 3CL
    Wang F; Liu D; Gao D; Yuan J; Zhao J; Yuan S; Cen Y; Lin GQ; Zhao J; Tian P
    Int J Biol Macromol; 2024 Apr; 264(Pt 1):130377. PubMed ID: 38395279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M
    Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
    Life Sci; 2020 Aug; 255():117831. PubMed ID: 32450166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent Docking.
    Vázquez-Mendoza LH; Mendoza-Figueroa HL; García-Vázquez JB; Correa-Basurto J; García-Machorro J
    Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seleno-Functionalization of Quercetin Improves the Non-Covalent Inhibition of M
    Mangiavacchi F; Botwina P; Menichetti E; Bagnoli L; Rosati O; Marini F; Fonseca SF; Abenante L; Alves D; Dabrowska A; Kula-Pacurar A; Ortega-Alarcon D; Jimenez-Alesanco A; Ceballos-Laita L; Vega S; Rizzuti B; Abian O; Lenardão EJ; Velazquez-Campoy A; Pyrc K; Sancineto L; Santi C
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34208928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Potent Pyrazoline-Based Covalent SARS-CoV-2 Main Protease Inhibitors.
    Moon P; Zammit CM; Shao Q; Dovala D; Boike L; Henning NJ; Knapp M; Spradlin JN; Ward CC; Wolleb H; Fuller D; Blake G; Murphy JP; Wang F; Lu Y; Moquin SA; Tandeske L; Hesse MJ; McKenna JM; Tallarico JA; Schirle M; Toste FD; Nomura DK
    Chembiochem; 2023 Jun; 24(11):e202300116. PubMed ID: 37069799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic flavonoids as potential antiviral agents against SARS-CoV-2 main protease.
    Batool F; Mughal EU; Zia K; Sadiq A; Naeem N; Javid A; Ul-Haq Z; Saeed M
    J Biomol Struct Dyn; 2022 May; 40(8):3777-3788. PubMed ID: 33251983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors.
    Gao S; Song L; Claff T; Woodson M; Sylvester K; Jing L; Weiße RH; Cheng Y; Sträter N; Schäkel L; Gütschow M; Ye B; Yang M; Zhang T; Kang D; Toth K; Tavis J; Tollefson AE; Müller CE; Zhan P; Liu X
    J Med Chem; 2022 Dec; 65(24):16902-16917. PubMed ID: 36475694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of M Protease Inhibitors Encoded by SARS-CoV-2.
    Hung HC; Ke YY; Huang SY; Huang PN; Kung YA; Chang TY; Yen KJ; Peng TT; Chang SE; Huang CT; Tsai YR; Wu SH; Lee SJ; Lin JH; Liu BS; Sung WC; Shih SR; Chen CT; Hsu JT
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32669265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating the binding energetics of reversible covalent inhibitors of the SARS-CoV-2 main protease: an
    Awoonor-Williams E
    Phys Chem Chem Phys; 2022 Oct; 24(38):23391-23401. PubMed ID: 36128834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-Based Discovery of Novel Nonpeptide Inhibitors Targeting SARS-CoV-2 M
    Yang J; Lin X; Xing N; Zhang Z; Zhang H; Wu H; Xue W
    J Chem Inf Model; 2021 Aug; 61(8):3917-3926. PubMed ID: 34279924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Isojacareubin as a covalent inhibitor of SARS-CoV-2 main protease using structural and experimental approaches.
    Khan A; Heng W; Imran K; Zhu G; Ji J; Zhang Y; Guan X; Ge G; Wei DQ
    J Med Virol; 2023 Feb; 95(2):e28542. PubMed ID: 36727647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining virtual screening with cis-/trans-cleavage enzymatic assays effectively reveals broad-spectrum inhibitors that target the main proteases of SARS-CoV-2 and MERS-CoV.
    Chang YJ; Le UNP; Liu JJ; Li SR; Chao ST; Lai HC; Lin YF; Hsu KC; Lu CH; Lin CW
    Antiviral Res; 2023 Aug; 216():105653. PubMed ID: 37321487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.